spacer
home > ebr > autumn 2019 > pet technology and tumour progression
PUBLICATIONS
European Biopharmaceutical Review

PET Technology and Tumour Progression




Positron emission tomography (PET) is a widely used imaging technique in nuclear medicine for both clinical diagnostics and preclinical applications. PET enables 3D functional imaging using radioactive tracers (radiotracers), highlighting the spatial distribution of biomolecular activity in the bodies of animal models and humans. In this context, PET imaging is increasingly being used by researchers in drug development as it provides data that can be extrapolated from animal to human studies. Small animal imaging deepens our understanding of disease development and the effect of potential treatments, advances in PET technology are powering the translation of this research into the clinical setting.

The numerous types of tumours including those not yet well characterised and their unpredictable reactions to treatment make the search for new effective cancer therapies incredibly challenging. Non-invasive in vivo imaging technologies such as PET allow researchers to better understand the course of tumour development by visualising cancer-related processes in real time. Such methods are enabling researchers to further their knowledge of tumour morphology, progression, and biomarker expression. PET is able to provide information on the expression of receptors, energy metabolism, and other biomarkers of tumours by imaging an intravenously injected radiotracer. This radiotracer comprised a radioisotope, most commonly fluorine-18 (18F), attached to a molecular probe that targets a specific molecule or metabolic pathway, and its uptake by tumour cells is monitored.

The combination of other imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), and single-photon emission computed tomography (SPECT), joins structural and functional imaging in one experiment. PET/CT, PET/MRI, and PET/SPECT/CT multimodal systems are able to provide quantitative 3D tomographic images of radiotracers, bone, and soft tissue, furthering the growing knowledge of cancer biology and treatment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Todd Sasser is Head of Applications for Bruker Preclinical Imaging. Todd works directly with research sites involved in PET applications across a wide variety of disciplines from infection imaging and cancer biology to probe development. He studied at the University of Liverpool, UK, and The University of Hawaii, US, and was a visiting scholar at The University of Notre Dame, France.
spacer
Dr Todd Sasser
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection Established platform technology to reliably scale target molecules Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement